ArticlePloS one2015
Development of small diameter nanofiber tissue engineered arterial grafts.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- An overview of recent flexible- and soft-biomaterial applications in myocardial infarction and other cardiovascular diseases.Materials today. Bio · 2026Review
- A Dual-Crosslinked Metallo-elastomer Platform for Architecture-Directed Vascular Remodeling.Advanced fiber materials · 2026Article
- Next-generation pediatric care: nanotechnology-based and AI-driven solutions for cardiovascular, respiratory, and gastrointestinal disorders.World journal of pediatrics : WJP · 2025Review
- Evaluation of in situ tissue-engineered arteriovenous grafts suitable for cannulation in a large animal model.Communications materials · 2025Article
- Fabrication of 3D Biomimetic Smooth Muscle Using Magnetic Induction and Bioprinting for Tissue Regeneration.Biomaterials research · 2024Article
- Review
- The effect of chronic kidney disease on tissue formation ofAPL bioengineering · 2023Article
- Rapid remodeling observed at mid-term in-vivo study of a smart reinforced acellular vascular graft implanted on a rat model.Journal of biological engineering · 2023Article
- Article
- Selection of different endothelialization modes and different seed cells for tissue-engineered vascular graft.Bioactive materials · 2021Review
- bFGF and SDF-1α Improve In Vivo Performance of VEGF-Incorporating Small-Diameter Vascular Grafts.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Collagen: quantification, biomechanics, and role of minor subtypes in cartilage.Nature reviews. Materials · 2020Article
- Article
- Regenerative and durable small-diameter graft as an arterial conduit.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Comparison of venous repair results using either arterial or vein grafts in a crush-avulsion injury modelTurkish journal of medical sciences · 2019Article
- Assessment of the Angiogenic Potential of 2-Deoxy-D-Ribose Using a NovelFrontiers in bioengineering and biotechnology · 2019Article
- Enhancing anti-thrombogenicity of biodegradable polyurethanes through drug molecule incorporation.Journal of materials chemistry. B · 2018Article
- Quickening: Translational design of resorbable synthetic vascular grafts.Biomaterials · 2018Review
- Building Blood Vessels with Vascular Progenitor Cells.Trends in molecular medicine · 2018Review
- Accurate and continuous ultrasonography evaluation of small diameter vascular prosthesesExperimental and therapeutic medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The surgical repair of heart and vascular disease often requires implanting synthetic grafts. While synthetic grafts have been successfully used for medium-to-large sized arteries, applications for small diameter arteries (<6 mm) is limited due to high rates of occlusion by thrombosis. Our objective was to develop a tissue engineered vascular graft (TEVG) for small diameter arteries. TEVGs composed of polylactic acid nanofibers with inner luminal diameter between 0.5 and 0.6 mm were surgically implanted as infra-renal aortic interposition conduits in 25 female C17SCID/bg mice. Twelve mice were given sham operations. Survival of mice with TEVG grafts was 91.6% at 12 months post-implantation (sham group: 83.3%). No instances of graft stenosis or aneurysmal dilatation were observed over 12 months post-implantation, assessed by Doppler ultrasound and microCT. Histologic analysis of explanted TEVG grafts showed presence of CD31-positive endothelial monolayer and F4/80-positive macrophages after 4, 8, and 12 months in vivo. Cells positive for α-smooth muscle actin were observed within TEVG, demonstrating presence of smooth muscle cells (SMCs). Neo-extracellular matrix consisting mostly of collagen types I and III were observed at 12 months post-implantation. PCR analysis supports histological observations. TEVG group showed significant increases in expressions of SMC marker, collagen-I and III, matrix metalloproteinases-2 and 9, and itgam (a macrophage marker), when compared to sham group. Overall, patency rates were excellent at 12 months after implantation, as structural integrity of these TEVG. Tissue analysis also demonstrated vessel remodeling by autologous cell.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.